<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773929</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-593_101</org_study_id>
    <nct_id>NCT00773929</nct_id>
  </id_info>
  <brief_title>Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer</brief_title>
  <official_title>A Multicenter Phase I Clinical and Pharmacokinetic Study of Oral TAK-593 in Subjects With Nonhematologic Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and toxicity profile of TAK-593 and
      determine the maximum tolerated dose of TAK-593.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicities of TAK-593 Pharmacokinetic parameters of TAK-593</measure>
    <time_frame>18-24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response outcomes including objective response and clinical benefit response.</measure>
    <time_frame>18-24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3-6 subjects each cohort. Escalate dose after safety evaluation of subjects in cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-593</intervention_name>
    <description>Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.
Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 18 years of age diagnosed with advanced solid tumor cancer that failed to respond to
             standard therapies and where no other treatment options are available.

          -  No prior chemotherapy

          -  Able to understand and follow study requirements

          -  Subject or subject's legal representative signs a written, informed consent form prior
             to beginning any study procedures.

          -  Women who are post-menopausal for at least 1 year before screening or surgically
             sterile

          -  Women of childbearing potential agree to practice two effective methods of birth
             control from the time of signing the informed consent form through 30 days after the
             last dose of the study drug or agree to completely abstain from heterosexual
             intercourse.

          -  Men who agree to practice an effective method of birth control for the entire study
             treatment period and through 30 days after the last dose of study drug or completely
             agree to abstain from heterosexual intercourse.

          -  Ability to swallow and retain oral medication

          -  Meet study specific laboratory test standards for bone marrow function, liver
             function, blood pressure, and renal function.

        Exclusion Criteria:

          -  Cancer has spread to the brain

          -  History of another cancer diagnosed or treated within the past 3 years.

          -  Severe cardiovascular issues including heart attack within the past 6 months, unstable
             angina or arrhythmias that require treatments.

          -  Severe thyroid disease

          -  Unstable angina

          -  Arrhythmia issues

          -  History of bleeding issues

          -  Serious wounds, ulcers or bone fractures that do not heal

          -  Subject is pregnant or breast feeding

          -  Subject has illnesses or conditions that may affect their ability to participate in
             the study

          -  Subject participated in another clinical study/post marketing clinical study within 4
             weeks prior to the start of this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2008</study_first_posted>
  <last_update_submitted>April 23, 2010</last_update_submitted>
  <last_update_submitted_qc>April 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Clinical Research Monitor</name_title>
    <organization>Millennium Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

